Journal
AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE
Volume 81, Issue 5, Pages 895-899Publisher
AMER SOC TROP MED & HYGIENE
DOI: 10.4269/ajtmh.2009.09-0189
Keywords
-
Funding
- World Health Organization
- Pacific Leprosy Trust (New Zealand)
- Sasakawa Memorial Health Foundation (Japan)
Ask authors/readers for more resources
From 1987 to 1994, we enrolled 500 subjects completing 2-year WHO multiple drug therapy (MDT) for multibacillary leprosy in a prospective relapse study. Relapse was defined as new skin lesions and an increase in the bacterial index (BI) >= 2+ (>= 100x) at any single slit-skin smear site. At the study end in 2006, follow-up was 6,401 subject-years, a mean of 12.8 years/subject. We observed 23 relapses, 6-16 years after MDT (mean, 10.5 years; 95% confidence interval [CI], 9.2-11.8), peaking in Years 11-12 (> 1%/year). The cumulative risk was 6.6% (95% Cl, 5.0-8.2%). In a subset of 181 subjects with pre-MDT average BI >= 4+, 11 relapses occurred (cumulative risk, 10.1%). In mouse footpad assays, Mycobacterium leprae from relapsed subjects were rifampin and clofazimine sensitive. Taken together, the data suggest relapses are related to activation of dormant organisms (persisters) not killed by MDT rather than new infection.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available